Examining the interaction between TGFBR3 and ESRRA in ovarian cancer prognosis

The authors found that ESRRA when co-expressed at high levels with TGF{beta}R3 may be prognostic for serous ovarian cancer overall survival in data from the Cancer Genome Atlas; however, this result was not validated in further datasets. A cell line was also identified in this study for future functional investigation of interactions between ESRRA and TGF{beta}R3 in the context of oestrogen signaling in order to further elucidate their potential roles as prognostic biomarkers for serous ovarian cancer.\n\nFUNDING SUPPORTThis work was supported by Cancer Research UK program A6689 (RB and CSWB) and the Medical Research Council (AP)\n\nCONFLICT OF INTEREST DISCLOSURESThe authors have declared no conflicts of interest.\n\nAUTHOR CONTRIBUTIONSCSWB designed the study. AP, CSWB, and RB developed the methodology. AP and CSWB collected the data. AP, CSWB, and RB wrote the manuscript. CSWB is responsible for the overall content.